Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

MEADOWLANDS DIAGNOSTICS LLC

NPI: 1114524071 · WOOD RIDGE, NJ 07075 · Clinical Medical Laboratory · NPI assigned 10/05/2020

$415K
Total Medicaid Paid
14,594
Total Claims
9,491
Beneficiaries
12
Codes Billed
2020-12
First Month
2023-06
Last Month

Provider Details

Authorized OfficialSAMUELS, REGINALD (CHIEF EXECUTIVE OFFICER)
NPI Enumeration Date10/05/2020

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2020 378 $18K
2021 6,472 $223K
2022 6,534 $166K
2023 1,210 $7K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 4,795 3,070 $285K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 3,642 2,368 $65K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 5,128 3,264 $54K
86769 205 200 $7K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 83 61 $2K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 23 22 $728.82
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 212 156 $60.90
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 219 163 $13.44
36415 Collection of venous blood by venipuncture 28 14 $0.00
80053 Comprehensive metabolic panel 40 20 $0.00
85025 Blood count; complete (CBC), automated, and automated differential WBC count 39 18 $0.00
80365 180 135 $0.00